Compare Cytokinetics Inc (CYTK) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs PAGSEG Inc — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while PAGSEG Inc trades at $9.04 (market cap $2.59B). The key difference: Cytokinetics Inc is far larger — about 4.3× PAGSEG Inc's market cap, and PAGSEG Inc pays a 11.21% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | PAGS | |
|---|---|---|
Market Cap | $11.12B | $2.59B |
Sector | Technology | Technology |
52-Week High | $87.26 | $12.00 |
52-Week Low | $33.23 | $7.75 |
Enterprise Value | $11.59B | $10.22B |
Dividend Yield | — | 11.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
PAGS trades at $9.28, up 0.32% on the day, with a bullish technical signal from moving averages. The stock shows strong value metrics with a P/E of 6.57 and P/S of 0.68, supported by solid profitability including a 10.4% net income margin. Recent Q1 2026 earnings missed expectations at $0.39 per share versus $0.40 expected, but Q4 2025 beat estimates. The company maintains robust cash flow from operations of $7.56 billion in 2025.
Outlook remains positive due to deep valuation discounts and analyst consensus favoring buys (62.5%). Key risks include Brazilian macroeconomic sensitivity and competitive pressures in digital banking. Upside potential hinges on execution in credit expansion and efficiency gains, with the stock positioned for recovery if rate cuts materialize in Brazil.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
